Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma

Sun, Hongbo; Chua, Mei‐Sze; Yang, Dorothy; Tsalenko, Anya; Peter, Brian J.; So, Samuel

doi:10.4137/bmi.s595

Cited by 26 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…similarly, the serum levels of β-catenin were also higher in patients with CH than in AsC patients and healthy controls. these data are in agreement with previous reports by sun et al (20), where higher serum level of β-catenin were measured in patients with HCC compared with those in CH patients. the authors of this study suggested that serum level of β-catenin could be used clinically to complement the current AFp diagnostic test for more accurate detection of early HCC.…”

Section: Serum Levels Of E-cadherin Icam-1 Mmp-2 Vegf Opnsupporting

confidence: 83%

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Zekri

Bahnassy²,

El-Din³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. the global rising incidence of hepatocellular carcinoma (HCC), which parallels the increase of hepatitis C virus (HCV) prevalence, has sparked a renewed interest in discovering additional HCC serum markers. In this study, we investigated the clinical use of serum e-cadherin, ICAM, MMp-2, VeGF, OpN and β-catenin as potential diagnostic makers for HCV/genotype 4-associated HCC. twenty cases of healthy subjects, 11 cases with asymptomatic HCV/genotype 4 carriers (AsC), 28 chronic hepatitis (CH) cases and 32 patients with HCC were enrolled in this study. serum levels of proteins were measured by a sandwich-enzyme-linked (eLIsA) assay. the diagnostic accuracy of each candidate marker was evaluated using receiver-operating characteristic (rOC) curve analysis, reporting the area under the curve (AUC) and its 95% confidence interval (CI). We demonstrated that serum β-catenin levels were significantly elevated in patients with HCC compared to those with CH, AsC and healthy controls. Among the six studied markers, β-catenin was also found to be the only marker that can significantly discriminate between patients with HCC and those with CH; therefore, β-catenin could be considered as a potential marker for early diagnosis of HCV-associated HCC in patients infected with HCV genotype 4. IntroductionHepatocellular carcinoma (HCC) is the fifth most common cancer and one of the leading causes of cancer death in the world (1). It has heterogeneous geographical distribution, with its greatest incidence in Asia and sub-saharan Africa, where hepatitis B infection is endemic (2). Its incidence has also been increasing steadily in the United states and Western europe due to the high prevalence of hepatitis C (3,4). egypt has the highest prevalence of hepatitis C virus (HCV) infection, with 14% of the population infected and seven million with chronic liver hepatitis (5,6). Little is known about the molecular mechanisms by which HCV initiates HCC. Molecular studies directed at mapping the etiology of HCV disease progression to HCC are expected to provide new insights on the management of this increasing problem and hence are of great global health interest. However, the lack of molecular makers that can characterize the stage of HCC, regardless of the etiologic factor, and tumor progression precludes the effective diagnosis and prognosis of HCC. Currently, HCC diagnosis relies on the radiology imaging systems, and elevated serum α-fetoprotein (AFp). serum AFp is not always elevated to a diagnostic level in all patients in small HCC, thus, considerable numbers of patients with more advanced stages would be missed unless other diagnostic tools are used (7,8). Moreover, the level of AFp may be elevated in non-malignant chronic liver diseases, including chronic hepatitis and cirrhosis (9,10). several biomarkers, such as des-γ-carboxyprothrombin/prothrombin induced by vitamin K absence-II, lens cularis agglutininreactive (AFp-L3), and glypican-3, have been examined for their ability to diagnose early HCC (11). However, there is a...

show abstract

Section: Serum Levels Of E-cadherin Icam-1 Mmp-2 Vegf Opnsupporting

confidence: 83%

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Zekri

Bahnassy²,

El-Din³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Our result indicated that it is possible to detect cancer-specific expression patterns using antisense transcripts. In this study, we also investigated the profile of sense transcripts, and expression changes in the gene, DPT (39), CXCL14 (40), HAMP (41), MAGE1A (42) were consistent with results of previous studies. In contrast to genes discussed above, some genes that were reported previously were not recognized in the present study.…”

Section: Discussionsupporting

confidence: 73%

Differential expression profiles of sense and antisense transcripts between HCV-associated hepatocellular carcinoma and corresponding non-cancerous liver tissue

et al. 2012

View full text Add to dashboard Cite

Abstract. Recent studies have demonstrated that natural antisense transcripts, which are complementary sequences to messenger RNA, have important cellular functions such as the stabilization and silencing of mRNA. However, the possible contribution of antisense transcripts in hepatocellular carcinoma (HCC) development has not been described. Therefore, we simultaneously investigated the sense and antisense transcripts of HCC and non-cancerous tissues to explore the possible contribution of antisense transcripts to HCC progression. RNA was prepared from 15 HCV-associated HCCs and from 6 corresponding non-cancerous tissues and was subjected to expression profile analysis of sense and antisense transcripts using a human custom microarray. Differential expression of 161 sense and 25 antisense transcripts was observed with more than 2-fold between HCC and non-cancerous tissue (p<0.001). The expression of the sense and antisense transcripts was used to cluster cancer and non-cancerous tissues, and the cancer and non-cancerous tissues were found to be clearly separated into different clusters. Additionally, the sense and antisense expression profiles were analyzed with regard to HCC differentiation (p<0.001), resulting in 71 sense and 43 antisense transcripts. These unique transcripts did not overlap with those found in the discrimination of HCC from non-cancerous tissues. When the HCC tissues were clustered by transcript expression, the antisense transcripts resulted in clustering of HCC that was consistent with grouping based on histology. These findings strongly indicate that the antisense transcripts together with the sense transcripts are involved in liver tumorigenesis.

show abstract

“…Levels were lower in women with breast cancer [92], prostate cancer [93], and hepatocellular cancer [94] than in those with benign diseases of the same organ. However, two studies of women with ovarian cancer showed discrepant results [95,96].…”

Section: Circulating Levelsmentioning

confidence: 84%

Insulin-like growth factor binding proteins 4-6

Bach¹

2015

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma

Cited by 26 publications

References 28 publications

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Differential expression profiles of sense and antisense transcripts between HCV-associated hepatocellular carcinoma and corresponding non-cancerous liver tissue

Insulin-like growth factor binding proteins 4-6

Contact Info

Product

Resources

About